

A study on the genotoxic activities of some new benzoxazoles

Emine Oksuzoglu · Ozlem Temiz-Arpaci · Betul Tekiner-Gulbas ·
Hatice Eroglu · Gulseren Sen · Sabiha Alper · Ilkay Yildiz · Nuran Diril ·
Esin Aki-Sener · Ismail Yalcin

Received: 8 November 2006 / Accepted: 1 March 2007 / Published online: 1 June 2007
© Birkhäuser Boston 2007

Abstract The *Bacillus subtilis* *rec* assay has been specially developed to detect DNA-damaging potential in chemicals, with the rationale based on the relative difference of survival of a DNA repair combination proficient strains and its deficient strain, which is interpreted as genotoxicity. The genotoxic activities of newly (1–6) and previously (7–18) synthesized various benzoxazoles and benzimidazoles were analyzed via the *B. subtilis* *rec* assay. Newly obtained benzoxazole and benzimidazole derivatives (1–6) were synthesized in the presence of polyphosphoric acid (PPA) and 6 N HCl, respectively to detect their DNA-damaging activities. Among the tested compounds, 6-methyl-2-(*o*-chlorophenyl)benzoxazole (9), 5-amino-2-(*p*-methylbenzyl)benzoxazole (4), 5-(*p*-fluorobenzamido)-2-phenylbenzoxazole (13), and 2-(*p*-methylaninophenyl)benzoxazole (18) showed genotoxic activities having Rec₅₀ values of 1.85, 1.74, 1.60, and 1.50 or S-probit values of 0.534, 0.482, 0.460, and 0.357, respectively. On the other hand, 2-(*p*-bromobenzyl)-5-methylbenzimidazole (6) and 2-benzyl-5-(*p*-fluorophenylacetamido)-benzoxazole (15) were exhibited a reverse effect that displayed a bacterial growth in the *rec*[−] strains while there was no any bacterial growth in *rec*⁺ strains at the same concentration.

Keywords *Bacillus subtilis* *rec* assay · Benzimidazoles · Benzoxazoles · DNA-damaging activity · Genotoxic activity

E. Oksuzoglu · H. Eroglu · G. Sen · N. Diril
Molecular Biology Department, Faculty of Science, Hacettepe University, Beytepe 06532, Ankara,
Turkey

O. Temiz-Arpaci · B. Tekiner-Gulbas · S. Alper · I. Yildiz (✉) · E. Aki-Sener · I. Yalcin
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ankara University, Tandogan
TR-06100, Ankara, Turkey
e-mail: iyildiz@pharmacy.ankara.edu.tr

Introduction


A number of anticancer chemotherapeutic agents are bifunctionally reactive and therefore can crosslink biological macromolecules, including DNA (Reddy and Vasquez, 2005). The ability of these DNA interstrand crosslinks to interfere with DNA transcription and replication and ultimately to cause cytotoxicity appears to be essential for anticancer activity. Both intra- and interstrand DNA crosslinks are formed by some of these agents, as well as DNA-protein crosslinks, all of which may contribute to their cytotoxicity and chemotherapeutic efficacy. DNA-binding drugs such as cisplatin are components of treatment regimens for various cancer types (Chang *et al.*, 1987; Huerta *et al.*, 2003). Several mechanisms have been implicated in cisplatin resistance, including reduced drug uptake, increased cellular thiol levels, increased or faulty DNA repair mechanisms, and a reduced level of apoptosis (Siddik, 2003).

Genotoxic agents are affecting nucleic acids and alter their function that may directly bind to DNA or they may indirectly lead to DNA damage by affecting enzymes involved in DNA replication (<http://www.Cancerquestorg/index-cfm?page0482>). If, DNA damage is severe enough, it will induce cells to undergo apoptosis, the equivalent of cellular suicide. The selectivity of the drug action is based on the sensitivity of rapidly dividing cells, such as cancer cells. Rapidly dividing cells are particularly sensitive to genotoxic agents because they are actively synthesizing new DNA. However, the genotoxic drugs affect both normal and cancerous cells, so that the genotoxicity of these drugs is one of their most serious side effects owing to the possibility of inducing secondary malignancies.

The substituted benzoxazole and benzimidazole derivatives have been the aim of many researches for many years because they constitute an important class of heterocyclic compounds exhibiting substantial antibacterial, antifungal, antitumor, and antiviral activities (Hubschwerlen *et al.*, 1992; Olsen *et al.*, 1994; Staszewski *et al.*, 1995; Kim *et al.*, 1996, 1997; Perrin *et al.*, 1996; Shi *et al.*, 1996; Zhou and Skibo, 1996; Pinar *et al.*, 2004; Plemper *et al.*, 2004; Yildiz *et al.*, 2004). A series of 5-formyl-, 5-(aminocarbonyl)-, or 5- and 6-nitro derivatives of 2-(4-methoxyphenyl)benzimidazoles and benzoxazoles were determined as topoisomerase I inhibitors (Kim *et al.*, 1996). Moreover, substituted pyrimido[1,6-*a*]benzimidazoles were also found as a new class of potent DNA gyrase inhibitors; however, their antibacterial activity was inferior to the quinolone type antibacterial agents such as norfloxacin or fleroxacin (Hubschwerlen *et al.*, 1992). Although benzoxazoles and benzimidazoles are the structural isomers of natural nucleotides and interact easily with the biopolymers, there were no genotoxic studies performed to date showing that these compounds may directly bind to DNA or may indirectly lead to DNA damage by affecting enzymes involved in DNA replication.

In previous studies, we reported some derivatives of benzoxazoles, benzimidazoles, and related fused heterocyclic compounds exhibiting antimicrobial (Yildiz *et al.*, 2004), antiviral (Plemper *et al.*, 2004), and multidrug resistance cancer cell activities (Lage *et al.*, 2006), with inhibiting activity on eukaryotic topoisomerase II enzyme in a cell-free system (Pinar *et al.*, 2004). In this study, a series of benzoxazole and benzimidazole derivatives **1–6** were synthesized and tested for

their genotoxic activity together with the previously synthesized analogs **7–18** (Sener *et al.*, 1991, 1997; Temiz *et al.*, 1998; Aki-Sener *et al.*, 2000; Yildiz *et al.*, 2004; Yildiz-Oren *et al.*, 1997, 2004) (Formula 1) by using the *B. subtilis* rec assay including their structure–activity relationship (SAR) studies. The goal of this study was to determine whether the synthesized compounds have any DNA-damaging genotoxic activity or not, which could be the mode of their chemotherapeutic action.



X= O, NH

Y= —, CH₂, CH₂O

A= C₆H₁₁, C₆H₅, C₆H₄

R= H, 5-Cl, 5-CH₃, 5-NH₂, 5-NO₂, 6-CH₃, 6-NO₂,

5-*p*-fluorobenzamido, 5-(*p*-fluorophenyl)acetamido,

5-(*p*-bromophenyl)acetamido

R₁= H, 2-Cl, 2-NO₂, 4-F, 4-Cl, 4-Br, 4-NH₂, 4-C₂H₅, 4-NHCH₃, 4-CH₃, 4-OC₂H₅

Formula 1

Materials and Methods

Chemistry

Silicagel HF₂₅₄ chromatoplates (0.3 mm) were used for thin-layer chromatography (TLC). The solvent systems were chloroform–methanol (15:0.5) for compounds **1–6**. All the melting points were taken on a Buchi SMP 20 capillary apparatus and are uncorrected. Infrared (IR) spectra were recorded via Pye Unicam SP-1025 with KBr discs. ¹H nuclear magnetic resonance (NMR) spectra were obtained via a Bruker AC 400 MHz spectrometer in d-chloroform or d₆-dimethyl sulfoxide, and tetramethylsilane (TMS) was used as an internal standard. Mass analyses were carried out with a Fisions-Instruments VG Platform II mass spectrometer using electron ionization. Elemental analyses were carried out with a Perkin Elmer model 240-C apparatus. The results of the elemental analyses (C, H, N) were within ± 0.4% of the calculated values. Physical and spectral data of the synthesized compounds are reported in Table 1.

General procedure for the synthesis of benzoxazole derivatives (**1–5**)

A mixture of 4-substituted-2-aminophenols (0.01 mol) and appropriate acids (0.015 mol) was heated over 100°C in polyphosphoric acid (PPA, 12 g) with stirring for 2.5 h according to Yildiz *et al.* (2004). At the end of the reaction period, the residue was poured into an ice-water mixture and neutralized with excess 10% NaOH solution

Table 1 Physical properties and spectral data of the synthesized compounds **1–6**


											
Compound no.	R	R ₁	X	Y	A	Formula	MP (°C)	Yield (%)	IR(cm ⁻¹)	¹ H-NMR(δ ppm, J=Hz)	MASS m/e
1	5-Cl 6-NO ₂	H	O	—	C ₆ H ₁₁	C ₁₃ H ₁₃ O ₃ N ₂ Cl	88	62	3098, 2936, 1606, 1531, 1448, 1333, 1255, 1013, 994–571	8.05 (1H, s), 7.78 (1H,s), 3.03–2.97 (1H, m), 2.19–2.15 (2H, m), 1.90–1.85 (2H, m), 1.77–1.65 (3H, m), 1.49–1.31 (3H, m)	281(% 100)(M ⁺)
2	5-NO ₂	OC ₂ H ₅	O	CH ₂	C ₆ H ₄	C ₁₆ H ₁₄ O ₄ N ₂	158	38	2976, 1611, 1514, 1451, 1339, 1244, 1018, 952–540	8.14–8.11 (1H,s), 7.31–7.29 (2H, d, J = 8.8), 7.26–7.24 (1H, d, J = 8.8), 6.94–6.92 (2H, d, J = 8.8), 6.89–6.87 (1H, d, J = 8.8), 4.23 (2H, s), 4.06–4.00 (2H, q), 1.37–1.33 (3H, t)	298 (%100)(M ⁺)
3	5-NH ₂	F	O	CH ₂	C ₆ H ₄	C ₁₄ H ₁₁ ON ₂ F	77	45	3382, 1599, 1563, 1453, 1355, 1300, 1223, 1014, 964–497	7.38–7.32 (2H, m), 7.25–7.22 (1H, d, J = 8.5), 7.05–7.0 (2H, m), 6.96–6.95 (1H, d, J = 2.21), 6.70–6.65 (1H, dd, J = 8.5, J' = 2.24), 4.20 (2H, s)	243(%) (M+1)
4	5-NH ₂	CH ₃	O	CH ₂	C ₆ H ₄	C ₁₅ H ₁₄ ON ₂	85	41	3382, 2917, 1615, 1556, 1453, 1355, 1272, 1021, 960–549	7.32–7.15 (5H, m), 6.98–6.95 (1H, d, J = 2.1), 6.67–6.64 (1H, dd, J = 8.5, J' = 2.19), 4.20 (2H, s), 2.35 (3H, s)	239(%) (M+1)

Table 1 continued

Compound no.	R	R ₁	X	Y	A	Formula	MP (°C)	Yield (%)	IR(cm ⁻¹)	¹ H-NMR(δ ppm, J=Hz)	MASS m/e
5	5-Cl	NH ₂	O	-	C ₆ H ₄	C ₁₃ H ₉ N ₂ OCl	197	45	3471, 3327, 1608, 1556, 1458, 1334, 1256, 944–535	7.84–7.81 (2H, d, J = 8.8), 7.72–7.71 (1H, d, J = 2.0), 7.68–7.66 (1H, d, J = 8.4), 7.32–7.30 (1H, dd, J = 8.4, J' = 2.4), 6.67–6.65 (2H, d, J = 8.8), 6.05 (2H, s)	245(%100)(M ⁺)
6	5-CH ₃	Br	NH	CH ₂	C ₆ H ₄	C ₁₅ H ₁₃ N ₂ Br	131	32	2918, 1630, 1553, 1445, 1178, 1012, 933–576	7.45–7.42 (1H, m), 7.38–7.36 (2H, d, J = 8.8), 7.28 (1H, s), 7.21–7.19 (1H, d, J = 8.4), 7.14–7.12 (2H, d, J = 8.0), 7.10–7.06 (1H, d, J = 8.0), 4.20 (2H, s), 2.40 (3H, s)	301(%100)(M ⁺)


extracted with benzene; the benzene solution was dried over anhydrous sodium sulfate and evaporated under diminished pressure. The residue was boiled with 200 mg of charcoal in ethanol and filtered and the solvent was removed with a rotary evaporator. The residue was purified via recrystallization from ethanol–water. The obtained needles are dried *in vacuo* (Scheme 1, routes I and II).

5-Methyl-2-(*p*-bromobenzyl)benzimidazole (6): A mixture of *p*-bromophenylacetic acid (0.01 mol) and 4-methyl-2-phenyldiamine (0.01 mol) was boiled under reflux with stirring for 4 h in 15 ml of 6 N HCl according to Sener *et al.* (1997). At the end of the reaction period, the mixture was neutralized with excess NaHCO_3 . The collected precipitate washed with water and dried *in vacuo*. The residue was purified by column chromatography, eluted with CHCl_3 , and the obtained product was recrystallized from ethanol–water and needles were dried *in vacuo* (Scheme 1, route III).



Genotoxic study

The *rec* assay was developed for screening chemical and environmental mutagens. Recombinationless mutant cells of *B. subtilis* (M45) are more sensitive to the cell-


Route I:



Route II:



Route III:



Scheme 1 General synthesis of compounds 1–6

killing action of chemical mutagens, e.g., mytomycin C, *N*-nitroso-*N*-methylurethane, etc., than are the wild-type bacteria (H17). The assay is also useful for prescreening anticancer drugs such as dynemicines. Because the sensitivity of the *rec* assay to chemicals having induction activity of DNA damage is higher than that of other screening systems, this method may be useful for prescreening bioactive compounds in crude drugs as well as in microorganisms (Nomura *et al.*, 2002).

Both bacterial strains *B. subtilis* H17 (*arg*[−], *trp*[−], *recE*⁺) and *B. subtilis* M45 (*arg*[−], *trp*[−], *recE*[−]) were obtained from National Institute of Genetics, Mishima, Shizuoka-Ken, Japan. The test consists of comparing the highly sensitive *rec*[−] (*B. subtilis* M45) strain with the wild-type *rec*⁺ (*B. subtilis* H17), the *rec*[−] strain being deficient in recombinant repair. The use of spores is preferred over vegetative cells as spores increase the sensitivity of the assay by 15–20 times over the germinating phase (Kada *et al.*, 1980). The induction of DNA damage and the efficacy of mutation induction were correlated via screening of positive mutagen agent, 4-nitroquinoline 1-oxide (4-NQO). In addition, the antineoplastic agent cisplatin was used as a standard drug. The strains were checked routinely for ultraviolet-light sensitivity and arginine and tryptophan requirements and stored at −80°C.

Preparation of spores

The spores were prepared by spreading overnight broth cultures of the strains in different sets of sterile disposable Petri plates on modified Schaeffer's agar medium (Sharma and Sobti, 2000). The plates were incubated at 37°C for 3 and 5 days for H17 and M45 strains, respectively. After incubation, the spores were scraped up, washed, and resuspended in fresh minimal salt solution containing 1 g of (NH₄)₂SO₄, 10 g of KH₂PO₄, 0.1 g of MgSO₄·7H₂O, and 0.5 g of sodium citrate. Thereafter, they were treated with lysozyme (2 mg/ml) and 1% sodium dodecyl sulfate (SDS) subsequently for 30 min each. The detergent was removed with subsequent washings (minimum of five washings) with sterile distilled water. Spores were suspended in sterile distilled water for storage at 4°C.

rec assay procedure

The *B. subtilis* *rec* assay was performed according to the liquid method of Kada using the strains *B. subtilis* H17 (*rec*⁺) and *B. subtilis* M45 (*rec*[−]) (Kada *et al.*, 1980). Compounds were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 2 mg/ml. Initially, 0.1-ml portions of the nutrient broth were poured into each well of a plastic 96-well microplate. Next, 0.1 ml of the solution with compounds was added to the first well and mixed. Then 0.1 ml of this mixture was poured into the second one. This procedure was repeated 10 times to prepare serial half-dilutions of the compounds (Sakagami *et al.*, 1988; Sharma and Sobti, 2000). Thereafter, the plates were inoculated with a 40-μl portion of spore solutions of *rec*⁺ and *rec*[−] (1.3×10^8), covered with lids, and incubated overnight at 37°C. The presence or absence of bacterial growth was checked by the measurement of the absorbance at a wavelength of 620 nm in all wells, and minimum inhibitory concentrations (MICs) were compared between *rec*⁺ and *rec*[−] strains. All experi-

ments were performed using three plates. At least three wells were used for each dose and each experiment was repeated three times. Based on the experimental results of the tested compounds, the ratio of 50% lethal dose (Rec_{50}) as given in the equation below was used to assess genotoxicity of the tested compounds (Sakagami *et al.*, 1988).

$$Rec_{50} \text{ value} = \frac{CR_{50} \text{ } rec^{+} \text{ (50\% lethal dose of } B. subtilis \text{ H17)}}{CR_{50} \text{ } rec^{-} \text{ (50\% lethal dose of } B. subtilis \text{ M45)}}$$

To describe the genotoxic potential of a sample, a survival curve was drawn with the logarithmic concentration on the abscissa and survival on the coordinate. The area enclosed between both survival curves of rec^{+} and rec^{-} corresponds to genotoxicity. With the Probit scale transformation, the two curves are converted to two linear functions (Fig. 1). Then the enclosed area between the two lines can be calculated by a simple integration. This integrated area, designated as the S-probit, is a quantitative index for evaluating genotoxic potential (Takigami *et al.*, 2002).

The DNA damaging potentials of the chemicals consist of four ranges of genotoxicity and the criteria of ranges of genotoxicity for S-probit and Rec_{50} values are given in Table 2 (Sakagami *et al.*, 1988)

Results and Discussion

Many clinically important chemotherapeutic drugs induce DNA interstrand crosslinks such as mitomycin C, cyclophosphamide, melphalan, nitrogen and sulfur mustards, cisplatin, and photoactivated psoralens exhibiting alkylating and/or DNA

Fig. 1 Survival curves for rec^{+} and rec^{-} tested with a typical genotoxic substance. Conversion to the Probit coordinate is shown on the right, where the S-probit is shown




Table 2 Criteria of ranges of genotoxicity for S-probit and Rec_{50} values

Evaluation of genotoxicity	Rec_{50}	S-probit
Strong genotoxic response (++)	>2	>0.593
Genotoxic response (+)	1.5–1.99	0.200–0.592
Nongenotoxic (–)	0.85–1.49	–0.123–0.199
Reverse effect (r)	<0.85	<–0.123

From Takigami *et al.* (2002)

photoreactive activities. Some of these compounds induce DNA monoadducts in addition to interstrand crosslinks. Compared to intrastrand crosslinks, interstrand crosslinks are more cytotoxic, mutagenic, and recombinogenic (Dronkert and Kanaar, 2001; Reddy and Vasquez, 2005).

In this study, a congeneric set of newly (1–6) and previously (7–18) (Sener *et al.*, 1991, 1997; Oren *et al.*, 1997; Temiz *et al.*, 1998; Aki-Sener *et al.*, 2000; Yildiz *et al.*, 2004; Yildiz-Oren *et al.*, 2004) (Formula 1) synthesized isosteric fused heterocyclic compounds of 2,5-disubstituted benzoxazole and benzimidazole derivatives were investigated for their potential *in vitro* genotoxicity by evaluating DNA-damage in the *B. subtilis* *rec* assay. This assay is a powerful method to recognize wide spectra of DNA damages including intercalation, breakage of DNA molecules, and chemical changes of DNA bases. It can detect mutagens at a much lower concentration than the *E. coli* and *Salmonella* mutation assays, owing to the high permeability of chemicals through the cell membrane of *B. subtilis* (Yamaguchi, 1989). Cisplatin (Sampedro *et al.*, 1991; Khokhar *et al.*, 1993), which is widely used as a cancer chemotherapeutic drug causing DNA damage, was chosen as a standard drug for comparing the activity with the tested compounds.

The rationale for the *B. subtilis* *rec* assay is based on the relative difference of survival of a DNA repair-recombination proficient strain (*rec*⁺) and its deficient strain (*rec*[−]), which is interpreted as genotoxicity. Recombinationless mutant cells of *B. subtilis* M45 *rec*[−] strains are more sensitive to the cell-killing action of chemical mutagens than the wild-type *B. subtilis* H17 *rec*⁺ strains. Because the sensitivity of the *rec* assay to chemicals having induction activity of DNA damage is higher than that from other screening techniques, this method is a useful tool for the observation of the genotoxic activity (Kada *et al.*, 1980; Konishi and Oki, 1995; Shi *et al.*, 2001). The *B. subtilis* *rec* assay was applied to various organic and inorganic chemicals including genotoxic and cytotoxic substances, and the criteria used to assess genotoxicity were derived from those results.

All genotoxic activity results of newly and previously synthesized compounds 1–18 together with the positive control reference agent 4-nitroquinoline 1-oxide (4-NQO) and the standard drug cisplatin were given in Table 3. The activity results showed that none of the tested compounds was found more genotoxic than the classical positive mutagen 4-NQO and the standard drug cisplatin. However, among the tested compounds, 6-methyl-2-(o-chloro-phenyl)benzoxazole (9), 5-amino-2-(p-methylbenzyl)benzoxazole (4), 5-(p-fluorobenzamido)-2-phenylbenzoxazole (13), and 2-(p-methylaminophenyl)benzoxazole (18) showed genotoxic activity, with Rec₅₀ values of 1.85, 1.74, 1.60, and 1.50 or S-probit values of 0.534, 0.482, 0.460, and 0.357, respectively. Compound 9 exhibited the most potent DNA-damaging property in this set of tested compounds, showing an S-probit value of 0.534 that was in part close to cisplatin. Interestingly, 2-(p-bromobenzyl)-5-methylbenzimidazole (6) and 2-benzyl-5-(p-fluorophenyl-acetamido)benzoxazole (15) exhibited a reverse effect that displayed a bacterial growth in the *rec*[−] strains while there was no any bacterial growth in *rec*⁺ strains at the same concentration.

Research conducted with bacterial systems has shown that compounds that cause DNA damage and induce the DNA repair system could also be promising as antitumoral agents in mammals, including humans, as repair-deficient persons

Table 3 Genotoxic activity of the tested compounds **1–18** shown as Rec₅₀ and S-Probit values


Compound no.							MIC ($\mu\text{g/ml}$) <i>rec</i> ⁺	MIC ($\mu\text{g/ml}$) <i>rec</i> [−]	Rec ₅₀ = CR ₅₀ (<i>rec</i> ⁺)/ CR ₅₀ (<i>rec</i> [−])	S-Probit
	A	X	Y	R	R ₁					
1	C ₆ H ₁₁	O	—	5-Cl, 6-NO ₂	H	500	500	1.25	0.190	
2	C ₆ H ₄	O	CH ₂	5-NO ₂	4-OC ₂ H ₅	500	500	1.27	0.220	
3	C ₆ H ₄	O	CH ₂	5-NH ₂	4-F	500	500	1.25	0.198	
4	C ₆ H ₄	O	CH ₂	5-NH ₂	4-CH ₃	500	500	1.74	0.482	
5	C ₆ H ₄	O	—	5-Cl	4-NH ₂	2000	2000	1.00	0	
6	C ₆ H ₄	NH	CH ₂	5-CH ₃	4-Br	30	125	0.49	−0.606	
7	C ₆ H ₄	O	CH ₂ O	5-Cl	4-Cl	500	500	1.00	0	
8	C ₆ H ₅	O	CH ₂ O	6-CH ₃	H	1000	1000	0.93	0.064	
9	C ₆ H ₄	O	—	6-CH ₃	2-Cl	125	60	1.85	0.534	
10	C ₆ H ₄	O	—	5-CH ₃	2-NO ₂	500	500	0.96	−0.046	
11	C ₆ H ₅	O	—	5-NO ₂	H	500	500	1.07	0.056	
12	C ₆ H ₁₁	NH	CH ₂	5-Cl	H	1000	500	0.93	−0.063	
13	C ₆ H ₅	O	—	5-(<i>p</i> -flurobenzamido)	H	1000	500	1.60	0.460	
14	C ₆ H ₄	O	—	5-(<i>p</i> -bromophenylacetamido)	4-C ₂ H ₅	500	500	0.95	−0.020	
15	C ₆ H ₅	O	CH ₂	5-(<i>p</i> -flurophenylacetamido)	H	500	500	0.58	−0.462	
16	C ₆ H ₄	O	CH ₂	5-Cl	4-Br	1000	1000	1.05	0.047	
17	C ₆ H ₄	O	—	5-NH ₂	4-Br	1000	1000	1.05	0.045	
18	C ₆ H ₄	O	—	H	4-NHCH ₃	1000	500	1.50	0.357	

Table 3 continued

Compound no.	A	X	Y	R	R ₁	MIC ($\mu\text{g/ml}$) <i>rec</i> ⁺	MIC ($\mu\text{g/ml}$) <i>rec</i> ⁻	Rec ₅₀ = CR ₅₀ (<i>rec</i> ⁺)/ CR ₅₀ (<i>rec</i> ⁻)	S-Probit
Cisplatin ^a	1000	1000	2.95	0.932					
4-Nitroquinoline 1-oxide (4-NQO) ^b	1000	60	2.21	0.690					

^a Standard drug

^b Positive mutagen reference agent

exhibit defects in their ability to repair damaged DNA and thus are prone to developing cancer (Sawicka *et al.*, 1991).

Structure–activity relationships in this set of tested compounds revealed that benzoxazole derivatives were more potent than benzimidazoles for the genotoxic activity. Benzoxazole derivatives possessing most of phenyl and/or rarely benzyl moieties on position 2 in the fused ring system rather than having phenoxyethyl and/or cyclohexyl groups and holding either an amino or *p*-fluorobenzamido groups on position 5 and/or methyl substitution on position 6 enhanced the genotoxic activity. In addition, when attaching a *p*-(methylamino)phenyl group at position 2 of the nonsubstituted, benzoxazole increased the activity. On the other hand, having *p*-fluorophenylacetamido group instead of *p*-fluorobenzamido at the fifth position of 2-benzylbenzoxazole structure showed a reverse effect in genotoxic activity (compare the *S*-probit values of compounds **15** and **13** in Table 3).

In conclusion, the *B. subtilis* *rec* assay results show that some of the benzoxazole derivatives have DNA-damaging genotoxic activity that should be considered in further studies.

Acknowledgments This study was supported by the Hacettepe University Research Fund (Grant 01.02.601.006), Ankara University Research Fund (Grant 2005-0803049), and TUBITAK (Grant TBAG-2088, 101T127).

References

- Aki-Sener E, Temiz-Arpaci O, Yalcin I, Altanlar N (2000) Synthesis and microbiological activity of some novel 5-benzamido- and 5-phenylacetamido- substituted 2-phenylbenzoxazole derivatives. *Farmacologia* 55:397–405
- Cancer quest: Cancer treatments: Chemotherapy genotoxic drugs: <http://www.Cancerquestorg/index-cfm? page0482>
- Chang BK, Gutman R, Chou TC (1987) Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. *Cancer Res* 47:2247–2250
- Dronkert ML, Kanaar R (2001) Repair of DNA interstrand cross-links. *Mutat Res* 486:217–247
- Hubschwerlen C, Pflieger P, Specklin JL, Gubernator K, Gmünder H, Angehrn P, Kompis I (1992) Pyrimido[1,6-*a*]benzimidazoles: a new class of DNA gyrase inhibitors. *J Med Chem* 35:1385–1392
- Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D (2003) Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. *Int J Oncol* 22:663–670
- Kada T, Hirano K, Shirasu Y (1980) Screening of environmental chemical mutagens by the *rec*-assay system with *Bacillus subtilis*. In: de Serres FJ, Hollaender, eds. *Chemical Mutagens Principles and Methods for Their Detection*, New York: Plenum Press, pp. 149–173
- Khokhar AR, Deng Y, Al-Baker S, Yoshida M, Siddik ZH (1993) Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes. *J Inorg Biochem* 51:677–687
- Kim JS, Sun Q, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1996) Structure–activity relationships of benzimidazoles and related heterocycles as topoisomerase I poisons. *Bioorg Med Chem* 4:621–630
- Kim JS, Yu C, Liu A, Liu LF, LaVoie EJ (1997) Terbenzimidazoles: influence of 2′-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. *J Med Chem* 40:2818–2824
- Konishi M, Oki T (1995) Enediyne Antibiotics as Antitumor Agents, Borders DB, Doyle TW, eds. New York: Marcel Dekker, pp. 301–325

- Lage H, Aki-Sener E, Yalcin I (2006) High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II targeting drugs 18— Synthesis and microbiological activity of some novel 5-benzamido- and 5-phenylacetamido- substituted 2-phenylbenzoxazole derivatives. *Int J Cancer* 1, 119:213–220
- Nomura T, Fukai T, Akiyama T (2002) Chemistry of phenolic compounds of licorice (*Glycyrrhiza* species) and their estrogenic and cytotoxic activities. *Pure Appl Chem* 74:1199–1206
- Olsen DB, Carroll SS, Culbertson JC, Shafer JA, Kuo LC (1994) Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor. *Nucleic Acids Res* 22:1437–1443
- Oren I, Temiz O, Yalcin I, Sener E, Akin A, Ucarturk N (1997) Synthesis and microbiological activity of 5(or 6)-methyl-2-substituted benzoxazole and benzimidazole derivatives. *Arzneim Forsch/Drug Res* 47(12):1393–1397
- Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loes S, Pechere M, et al. (1996) Combined therapy with zidovudine and L-697, 661 in primary HIV infection. *AIDS* 10:1233–1237
- Pinar A, Yurdakul P, Yildiz-Oren I, Temiz-Arpaci O, Acan NL, Aki-Sener E, Yalcin I (2004) Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors. *Biochem Biophys Res Commun* 317:670–674
- Plempner RK, Erlandson KJ, Lakdawala AS, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B, Liotta DC, Snyder JP, Compans RW (2004) A target site for template-based design of measles virus entry inhibitors. *PNAS* 101:5628–5633
- Reddy MC, Vasquez KM (2005) Repair of genome destabilizing lesions. *Radiat Res* 164:345–356
- Sakagami Y, Yasamaki K, Yokoyama H, Ose Y, Sato (1988) T DNA repair test of disinfectants by liquid *rec*-assay. *Mutat Res* 193:21–30
- Sampedro F, Molins-Pujol AM, Bonal J, Barbe J, Garrido S, Pueyo M, Liagostera M, Sanchez-Ferrando F (1991) Sulfide and phosphine ligands in carboplatin analogs. *Eur J Med Chem* 26:539–543
- Sawicka J, Youyou N, Swiatek J, Decock P, Blondeau H, Lenormand I (1991) Synthesis and coordination ability of substituted imidazo-pyridines, structural analogues of oxine. Influence of copper(II) and nickel(II) ions on toxicity of the organic ligand. *J Inorg Biochem* 44:117–125
- Sener E, Yalcin I, Sungur E (1991) QSAR of Some antifungal benzoxazoles and oxazolo (4,5-*b*)pyridines against *C. albicans*. *QSAR* 10:223–228
- Sener E, Yalcin I, Temiz O, Oren I, Akin A, Ucarturk N (1997) Synthesis and structure–activity relationships of some 2,5-disubstituted benzoxazoles and benzimidazoles as antimicrobial agents. *Farmaco* 52:99–103
- Sharma MK, Sobti RC (2000) Rec effect of certain textile dyes in *Bacillus subtilis*. *Mutat Res* 465:27–38
- Shi DF, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, Stevens MFG (1996) Antitumor benzothiazoles 31 synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines *in vitro* and *in vivo*. *J Med Chem* 39:3375–3384
- Shi YQ, Fukai H, Sakagami H, Kuroda J, Miyaoka R, Tamura M, Yoshida N, Nomura T (2001) Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. *Anticancer Res* 21:2847–2854
- Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* 22:7265–7279
- Staszewski S, Massari FE, Kober A, Göhler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al. (1995) Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. *J Infect Dis* 171:1159–1165
- Takigami H, Matsui S, Matsuda T, Shimizu Y (2002) The *Bacillus subtilis* *rec*-assay: a powerful tool for the detection of genotoxic substances in the water environment Prospect for assessing potential impact of pollutants from stabilized wastes. *Waste Management* 22:209–213
- Temiz O, Oren I, Sener E, Yalcin I, Ucarturk N (1998) Synthesis and microbiological activity of some novel 5- or 6-methyl-2-(2,4-disubstituted phenyl) benzoxazole derivatives. *Farmaco* 53:337–341
- Yamaguchi T (1989) Mutagenic activity of various kinds of cheese on the Ames, *rec* and umu assays. *Mutat Res* 224:493–502
- Yildiz I, Yalcin I, Aki-Sener E, Ucarturk N (2004) Synthesis and structure–activity relationships of new antimicrobial active multisubstituted benzazole derivatives. *Eur J Med Chem* 39:291–298
- Yildiz-Oren I, Tekiner B, Yalcin I, Temiz-Arpaci O, Aki-Sener E, Altanlar N (2004) Synthesis and antimicrobial activity of new 2-[*p*-substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles. *Arch Pharm Pharm Med Chem* 337:402–410

- Zhou R, Skibo EB (1996) Chemistry of the pyrrolo[1,2-a]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II. *J Med Chem* 39:4321–4331